Voyager Therapeutics Announces CEO Succession Plan for 2018

Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases announced plans during 2018 for Steven Paul, M.D., to transition from president and chief executive officer of Voyager Therapeutics to executive science advisor.

As quoted in the press release:

“Steve has been an integral part of creating the foundation for Voyager, advancing the lead and pipeline programs, its gene therapy platform and manufacturing capabilities, and assembling a superb leadership team that will continue the mission of building a world-class company,” said Mark Levin, partner of Third Rock Ventures and chairman of the Voyager Board of Directors. “The Board is grateful to Steve’s many contributions over the years and for his commitment to remain a part of Voyager’s success going forward.”

Click here to read the full press release.